Acceptance and Commitment Therapy for Depressed People With Spinal Cord Injuries
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jan 27, 2024
Trial Information
Current as of March 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how an 8-week online program called Acceptance and Commitment Therapy (ACT) can help people with spinal cord injuries (SCI) who are experiencing depression. ACT is a type of therapy that teaches people to accept their thoughts and feelings rather than fight against them, which can lead to improved mental health and a better quality of life. The researchers aim to find out if those who participate in the ACT program will show improvements in their depressive symptoms compared to those who do not receive the therapy during the study.
To be eligible for this trial, participants must be adults aged 18 and older, living in the community with a spinal cord injury, and experiencing at least mild depression. They should also have access to a computer or smartphone with the internet. Participants will either take part in the ACT sessions through videoconferencing, guided by a coach, or be placed in a wait-list control group where they continue their usual care. After the study, those in the wait-list group will also have the chance to receive the therapy. Throughout the trial, researchers will check in on participants' mental health at different times to see how they are doing.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • community-dwelling adults (aged 18 years or older) living with spinal cord injuries
- • having at least mild depressive symptoms as measured by the PHQ-9 (scores ≥ 5)
- • having a web-enabled device (e.g., a computer or a smartphone) with internet access
- Exclusion Criteria:
- • having cognitive deficits or language barriers that might impede study participation
- • having suicidal intent or attempts in the past 6 months
- • having psychiatric hospitalizations in the previous 2 years
- • having a diagnosis with bipolar disorder or psychotic disorders (e.g., schizophrenia)
- • having a prior experience with acceptance and commitment therapy
Trial Officials
Areum Han, PhD
Principal Investigator
University of Alabama at Birmingham
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Birmingham, Alabama, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0